Abstract: IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are disclosed. The IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are IL-7R agonists.

Abstract: Described herein are interleukin-18 receptor binding moieties and uses thereof. An interleukin-18 receptor binding moiety can be an interleukin-18 receptor agonist or antagonist. An interleukin-18 receptor agonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. An interleukin-18 receptor antagonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists can be formulated in a pharmaceutical formulation.

Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Abstract: The use of IL-2R??c agonist peptides in cell manufacturing is disclosed. The IL-2R??c agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-2R??c agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.

Abstract: The use of IL-7R??c agonist peptides in cell manufacturing is disclosed. The IL-7R??c agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-7R??c agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.

Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.

Abstract: IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are disclosed. The IL-7R??c ligands and IL-7R??c IgG-Fc fusion proteins are IL-7R agonists.

Abstract: IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Abstract: Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.

Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.

Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.

Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.

Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.

Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.

Abstract: IL-2R? ligands and IL-2R?c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R? ligands and/or the IL-2R?c ligands can be IL-2 receptor agonists.

Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Abstract: IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, an autoimmune disease, and an inflammatory disease.

Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.

Abstract: IL-7R? ligands and compounds comprising IL-7R? ligands are disclosed. The IL-7R? binding compounds include fusion proteins comprising the IL-7R? ligands and can act as IL-7R agonists.